<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04127864</url>
  </required_header>
  <id_info>
    <org_study_id>TruCulture</org_study_id>
    <nct_id>NCT04127864</nct_id>
  </id_info>
  <brief_title>Perioperative Immune Function in Patients Undergoing Colorectal Cancer Surgery</brief_title>
  <acronym>TruCulture</acronym>
  <official_title>Perioperative Immune Function in Patients Undergoing Colorectal Cancer Surgery Using a Functional Whole Blood Immune Stimulation Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At Zealand University Hospital, Denmark, the investigators will examine the immune function
      of patients with colorectal cancer before and after tumor resection.

      The immune function will be assessed with functional profiling of the immune function
      (TruCulture®)

      The study aims to describe alterations in the perioperative immune response to surgery. The
      generatied knowledge will lead to better under standing of perioperative pathophysiology.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokines in LPS stimulated blood</measure>
    <time_frame>Postoperative day 1</time_frame>
    <description>Difference in cytokine levels (tumor necrosis factor alpha (TNF-a), interleukin-1b (IL-1b), interleukin -2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-11 (IL-11), interleukin-15 (IL-15), interleukin-17a (IL-17a), interleukin-17f (IL-17f), interleukin-18 (IL-18), interleukin-22 (IL-22) and GM-CSF, all pg/ml) between postoperative and preoperative whole blood exposed to lipopolysaccharide measured with multiplex assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokines in CD3+CD28 stimulated blood</measure>
    <time_frame>Postoperative day 1</time_frame>
    <description>Difference in cytokine levels (tumor necrosis factor alpha (TNF-a), interleukin-1b (IL-1b), interleukin -2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-11 (IL-11), interleukin-15 (IL-15), interleukin-17a (IL-17a), interleukin-17f (IL-17f), interleukin-18 (IL-18), interleukin-22 (IL-22) and GM-CSF, all pg/ml)between postoperative and preoperative whole blood exposed to CD3 and CD28 with multiplex assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokines in Poly I:P stimulated blood</measure>
    <time_frame>Postoperative day 1</time_frame>
    <description>Difference in cytokine levels (tumor necrosis factor alpha (TNF-a), interleukin-1b (IL-1b), interleukin -2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-11 (IL-11), interleukin-15 (IL-15), interleukin-17a (IL-17a), interleukin-17f (IL-17f), interleukin-18 (IL-18), interleukin-22 (IL-22) and GM-CSF, all pg/ml)between postoperative and preoperative whole blood exposed to Polyinosinic:polycytidylic acid with multiplex assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokines in R848 stimulated blood</measure>
    <time_frame>Postoperative day 1</time_frame>
    <description>Difference in cytokine levels (tumor necrosis factor alpha (TNF-a), interleukin-1b (IL-1b), interleukin -2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-11 (IL-11), interleukin-15 (IL-15), interleukin-17a (IL-17a), interleukin-17f (IL-17f), interleukin-18 (IL-18), interleukin-22 (IL-22) and GM-CSF, all pg/ml)between postoperative and preoperative whole blood exposed to Resiquimod (R848) with multiplex assay</description>
  </primary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Surgery</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colorectal cancer surgery</intervention_name>
    <description>All participants will undergo surgery for colorectal cancer.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for minimally invasive colorectal cancer resection at Zealand University
        Hospital. They will undergo standard treatment characterized by strict adherence to the
        enhanced recovery after surgery guidelines
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for laparoscopic resection of colorectal cancer with curative
             intent

        Exclusion Criteria:

          -  Age under 18

          -  Neoadjuvant chemo or radiation therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ismail Gögenur, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Center for Surgical Science, Zealand University Hospital, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Surgical Science, Zealand University Hospital</name>
      <address>
        <city>Køge</city>
        <state>Region Zealand</state>
        <zip>DK4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zealand University Hospital</investigator_affiliation>
    <investigator_full_name>Rune Børch Hasselager</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

